Helical SISLOT vascular reperfusion mosaic is diffusion-dominant with bimodal dFdCTP profile
Targeted radiation creates a pressure map in pancreatic tumors that could finally let chemotherapy reach the right cells.
HDR Ho-166 peak-zone vascular ablation + valley-zone normalization mosaic
6 bridge concepts›
How this score is calculated ›How this score is calculated ▾
6-Dimension Weighted Scoring
Each hypothesis is scored across 6 dimensions by the Ranker agent, then verified by a 10-point Quality Gate rubric. A +0.5 bonus applies for hypotheses crossing 2+ disciplinary boundaries.
Is the connection unexplored in existing literature?
How concrete and detailed is the proposed mechanism?
How far apart are the connected disciplines?
Can this be verified with existing methods and data?
If true, how much would this change our understanding?
Are claims supported by retrievable published evidence?
Composite = weighted average of all 6 dimensions. Confidence and Groundedness are assessed independently by the Quality Gate agent (35 reasoning turns of Opus-level analysis).
RQuality Gate Rubric
1/10 PASS · 9 CONDITIONAL
| Criterion | Result |
|---|---|
| Impact | 7 |
| Novelty | 7 |
| Groundedness | 6 |
| Falsifiability | 7 |
| Counter-Evidence | 7 |
| Cross Domain Bridge | 8 |
| Consistency | 8 |
| Mechanism | 9 |
| Translational Realism | 7 |
| Computational Plausibility | 8 |
Claim Verification
Empirical Evidence
How EES is calculated ›How EES is calculated ▾
The Empirical Evidence Score measures independent real-world signals that converge with a hypothesis — not cited by the pipeline, but discovered through separate search.
Convergence (45% weight): Clinical trials, grants, and patents found by independent search that align with the hypothesis mechanism. Strong = direct mechanism match.
Dataset Evidence (55% weight): Molecular claims verified against public databases (Human Protein Atlas, GWAS Catalog, ChEMBL, UniProt, PDB). Confirmed = data matches the claim.
Pancreatic cancer is notoriously hard to treat partly because the tumor is surrounded by a dense, fibrous shell — think of it like a fortress wrapped in thick concrete — that physically blocks drugs from getting in. On top of that, fluid pressure inside the tumor is extremely high, like an overfilled water balloon, which pushes drugs back out before they can do their job. Meanwhile, a cutting-edge radiation technique called spatially fractionated therapy deliberately delivers radiation in a checkerboard pattern: some zones get a lethal dose, others get a gentler 'valley' dose. The idea is that killing cells in the high-dose zones might somehow benefit the surrounding tissue too. This hypothesis proposes a surprisingly specific mechanism for how that might work — and it's all about fluid physics. When the high-dose 'peak' zones are ablated, those patches of tumor stop producing the metabolic fluid that drives internal pressure up. The neighboring low-dose 'valley' zones, if their blood vessels are normalized rather than destroyed, could then develop proper lymphatic drainage that actually lowers pressure. The hypothesis predicts that this creates a sharp pressure cliff at the boundary between dead and living tissue — roughly the width of a few capillaries. On one side of that cliff, drug movement is dominated by convective flow (like water pushed through a pipe); on the other side, deeper into the valley, drugs move by simple diffusion (like a drop of dye spreading in still water). The result: a distinctive double-peaked pattern of drug accumulation — high near the edges of each valley, lower in the middle, then high again near the next edge. That specific 'bimodal' fingerprint is what distinguishes this refined theory from earlier, simpler models. Why does this matter? Because if the drug delivery landscape inside a treated pancreatic tumor has this predictable spatial structure, then oncologists could potentially design treatment schedules — timing chemotherapy to coincide with the pressure normalization window, or adjusting the geometry of the radiation pattern — to maximize how much drug actually reaches live cancer cells. It turns the tumor microenvironment from an obstacle into something you could engineer.
This is an AI-generated summary. Read the full mechanism below for technical detail.
Why This Matters
If confirmed, this hypothesis could reshape how radiation and chemotherapy are sequenced and timed in pancreatic cancer treatment — one of the deadliest and most drug-resistant cancers we know. Specifically, it suggests there is a narrow but exploitable window after spatially fractionated radiation when chemotherapy drugs like gemcitabine could penetrate tumors far more effectively than usual, and that the geometry of the radiation pattern could be optimized to maximize this effect. It could also validate the use of holmium-166 — a rare element that doubles as both a therapeutic radiation source and an imaging agent — as a uniquely trackable tool for personalizing treatment in real time. The testable prediction (a bimodal drug distribution measurable by high-resolution tissue analysis) means this isn't just theoretical: a well-designed mouse or ex vivo human tissue study could confirm or refute the core mechanism, making it a scientifically tractable and clinically meaningful question to pursue.
Mechanism
H6 assumed convective Darcy-flow dominance for drug delivery through the vascular mosaic. Critic question #8 challenged this: in human PDAC where baseline IFP is 70-130 mmHg, is convective flow actually the dominant transport mode after peak-zone ablation, or does the collapse of IFP at peak/valley boundaries switch drug transport to diffusion-dominated? E3 resolves this by explicitly mutating the transport model from Darcy-convective to Fick-diffusion-dominant, while preserving the geometric mosaic prediction. Quantitative analysis: after peak-zone HDR ablation, the necrotic core loses active metabolic fluid production (hydraulic conductance collapses); the valley-zone vascular normalization establishes lymphatic drainage that actively removes interstitial fluid pressure. The resulting IFP gradient at the peak/valley boundary: Delta-IFP approximately 70-130 mmHg (peak side) to < 30 mmHg (valley side) across a boundary of width approximately 200-500 microns (one capillary transit distance). For convective Darcy transport to dominate, we need the Peclet number Pe = v_conv L / D_diff to exceed 1. With hydraulic conductivity K approximately 10^-7 cm/s/cmH2O (human PDAC stroma, Jain 2002), Delta-IFP = 100 mmHg = 136 cmH2O, boundary length L = 500 microns: v_conv = K Delta-IFP / L approximately 10^-7 136 / 0.05 approximately 2.7 x 10^-4 cm/s. Gemcitabine diffusivity in PDAC stroma approximately 5 x 10^-7 cm^2/s (collagen-gel literature), giving Pe = 2.7x10^-4 0.05 / 5x10^-7 approximately 27. Pe >> 1 confirms convective dominance AT THE BOUNDARY. However, away from the sharp boundary (at distances > 1 mm into the valley), the IFP gradient decays exponentially and Pe drops below 1; drug transport becomes diffusion-dominated in valley bulk. E3 therefore makes a more granular prediction: drug delivery in the first 500 microns from a peak/valley interface is convection-enhanced; drug delivery beyond 500 microns into valley bulk is Fick diffusion. This predicts a bimodal dFdCTP profile across the valley: high at the interface edges (within 500 microns), lower in the valley center (1.5-2 mm from both interfaces), then rising again at the opposite interface. This bimodal gradient is testable by LC-MS microdissection at 250-micron resolution and is the key distinguishing prediction of E3 versus H6's uniform mosaic model. The corrected endothelial ablation threshold: 8-10 Gy (Garcia-Barros 2003 Science, Moghaddasi 2022), not 30 Gy. Ho-166 peak doses far exceed both thresholds (100-300x), so the mechanism conclusion is unchanged.
Supporting Evidence
Garcia-Barros 2003 PMID 12750523 endothelial threshold 8-10 Gy; Moghaddasi 2022 SFRT vascular effects DOI 10.3390/ijms23063366; McMillan 2024 valley-dose vascular normalization
How to Test
{
"phase_1": "Candiolo IRCCS, 6 months: KPC organoid-microvasculature system with SISLOT-equivalent dose pattern; live fluorescence imaging of gemcitabine-FITC analog perfusion at peak/valley interface vs valley center at 1, 3, 7, 14 days; IFP proxy by osmometry of interstitial fluid; anti-VEGF-C blocking arm.",
"phase_2": "Candiolo, 12 months: Orthotopic KPC with SISLOT + day-7 gemcitabine; 250-micron microdissection LC-MS for dFdCTP at peak/valley interface vs valley center vs peak zones; wick-in-needle IFP at matching locations; MVD by CD31 spatial IHC; arms: SISLOT+gem, SISLOT+gem+anti-VEGF-C, IORT+gem, sham+gem.",
"phase_3": "Gemelli IRCCS, 24-36 months: Prospective Phase II resectable PDAC post-NCT05191498 successor; SISLOT at Whipple + adjuvant gem/nab-paclitaxel starting day 7 vs day 14; primary endpoint 18-month RFS; secondary: day-7 contrast MRI perfusion mosaic (peak/valley interface enhancement pattern) as imaging surrogate for bimodal drug delivery gradient; optional fine-needle day-7 biopsy for dFdCTP."
}
Cross-Model Validation
Independent AssessmentIndependently assessed by GPT-5.5 Pro and Gemini Deep Research Max for triangulation. Assessed independently by two external models for triangulation.
Other hypotheses in this cluster
In post-Whipple PDAC anatomy, Ho-166 SISLOT geometrically spares the SMA TDLN basin
A radioactive implant placed at surgical margins could kill pancreatic cancer cells while leaving nearby immune nodes intact to fight the disease.
Helical SISLOT valley-dose cGAS-STING activation in PDAC iCAFs is co-stimulation-dependent (50 nM EC50)
A targeted radiation technique might reprogram pancreatic cancer's protective shield cells into immune recruiters — if the dose is just right.
SISLOT valley-dose IGF-1R-AKT-IL-33 release as chemotactic beacon for gut-derived KLRG1+ ILC2s
Radiation therapy's 'low-dose zones' may act as molecular beacons that lure immune cells to build anti-tumor structures in pancreatic cancer.
SMA TDLN sparing with KRAS-driven baseline dysfunction stratification - double-gate functional readiness
A two-lock system to find the rare pancreatic cancer patients whose immune nodes can actually fight back after radiation.
Can you test this?
This hypothesis needs real scientists to validate or invalidate it. Both outcomes advance science.